"The U.S. Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis
Cystic fibrosis is a genetic disease that affects about 30,000 pediatric and adult patients in the United "...
- VPRIV should be administered under the supervision of a healthcare professional. VPRIV is a treatment that is given intravenously (by IV) every other week. The infusion typically takes up to 60 minutes.
- Patients should be advised that VPRIV may cause hypersensitivity reactions or infusion-related reactions. Infusion-related reactions can usually be managed by slowing the infusion rate, treatment with medications such as antihistamines, antipyretics and/or corticosteroids, and/or stopping and resuming treatment with increased infusion time. Pre-treatment with antihistamines and/or corticosteroids may prevent subsequent reactions. Treatment with VPRIV should be carefully re-evaluated if significant evidence of hypersensitivity to the product occurs [see WARNINGS AND PRECAUTIONS].
Last reviewed on RxList: 7/26/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional VPRIV Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.